ES2165061T3 - Derivados de 4-aralquilaminopirimidina biciclicos utilizados como inhibidores de la tirosina kinasa. - Google Patents

Derivados de 4-aralquilaminopirimidina biciclicos utilizados como inhibidores de la tirosina kinasa.

Info

Publication number
ES2165061T3
ES2165061T3 ES97925987T ES97925987T ES2165061T3 ES 2165061 T3 ES2165061 T3 ES 2165061T3 ES 97925987 T ES97925987 T ES 97925987T ES 97925987 T ES97925987 T ES 97925987T ES 2165061 T3 ES2165061 T3 ES 2165061T3
Authority
ES
Spain
Prior art keywords
component
alchylaminopirimidine
kinasa
bicyclic
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97925987T
Other languages
English (en)
Inventor
Maria Gabriella Brasca
Dario Ballinari
Antonio Longo
Franco Buzzetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2165061T3 publication Critical patent/ES2165061T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UNA COMPOSICION CURABLE COMPRENDIENDO: (A) UN COMPONENTE DE RESINA TERMOESTABLECIDA; (B) UN COMPONENTE DE AGENTE PARA CURACION; (C) UNA CANTIDAD DE UN COMPONENTE TERMOPLASTICO; Y (D) UN COMPONENTE CATALITICO ORGANOMETALICO DE CURACION, PRE-PEG, COMPOSITE CURADO Y PRODUCTO FORMADO QUE COMPRENDE LA COMPOSICION Y LOS PROCESOS PARA LA PREPARACION DE ELLOS; Y USO DE LOS COMPUESTOS DEL COMPONENTE D) Y SOPORTES DE MOLDEADO PARA SU PREPARACION.
ES97925987T 1996-06-21 1997-06-03 Derivados de 4-aralquilaminopirimidina biciclicos utilizados como inhibidores de la tirosina kinasa. Expired - Lifetime ES2165061T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613021.6A GB9613021D0 (en) 1996-06-21 1996-06-21 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2165061T3 true ES2165061T3 (es) 2002-03-01

Family

ID=10795666

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97925987T Expired - Lifetime ES2165061T3 (es) 1996-06-21 1997-06-03 Derivados de 4-aralquilaminopirimidina biciclicos utilizados como inhibidores de la tirosina kinasa.

Country Status (20)

Country Link
US (1) US6057326A (es)
EP (1) EP0853616B1 (es)
JP (1) JPH11511761A (es)
KR (1) KR19990043993A (es)
CN (1) CN1198158A (es)
AR (1) AR008614A1 (es)
AT (1) ATE205836T1 (es)
AU (1) AU3094197A (es)
BR (1) BR9702328A (es)
CA (1) CA2228492C (es)
DE (1) DE69706823T2 (es)
EA (1) EA199800215A1 (es)
ES (1) ES2165061T3 (es)
GB (1) GB9613021D0 (es)
HU (1) HUP9902026A3 (es)
IL (1) IL123124A0 (es)
NO (1) NO980718L (es)
PL (1) PL325122A1 (es)
WO (1) WO1997049689A1 (es)
ZA (1) ZA975380B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6347480B1 (en) * 1997-07-07 2002-02-19 Southpac Trust International, Inc. Method for wrapping a floral grouping with a sheet of material constructed of paper and having printed and embossed patterns thereon
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
AU2005214373B2 (en) * 2004-02-19 2011-07-28 Rexahn Corporation Quinazoline derivatives and therapeutic use thereof
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7358256B2 (en) * 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
JP5781934B2 (ja) * 2008-11-10 2015-09-24 ナショナル ヘルス リサーチ インスティテューツ チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
TW201249844A (en) * 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
EP3947390A4 (en) * 2019-04-03 2022-11-30 Mitokinin, Inc. COMPOSITIONS AND METHODS FOR THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT198900008A (es) * 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
JP2762430B2 (ja) * 1991-01-18 1998-06-04 宇部興産株式会社 アラルキルアミノピリミジン類の製法
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06172321A (ja) * 1992-10-08 1994-06-21 Agro Kanesho Co Ltd 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation

Also Published As

Publication number Publication date
AR008614A1 (es) 2000-02-09
EP0853616A1 (en) 1998-07-22
JPH11511761A (ja) 1999-10-12
US6057326A (en) 2000-05-02
BR9702328A (pt) 1999-07-20
HUP9902026A3 (en) 2000-07-28
ATE205836T1 (de) 2001-10-15
CA2228492C (en) 2007-05-08
DE69706823D1 (en) 2001-10-25
NO980718L (no) 1998-04-08
MX9801408A (es) 1998-05-31
IL123124A0 (en) 1998-09-24
AU3094197A (en) 1998-01-14
GB9613021D0 (en) 1996-08-28
DE69706823T2 (de) 2002-04-11
KR19990043993A (ko) 1999-06-25
CN1198158A (zh) 1998-11-04
ZA975380B (en) 1998-01-05
PL325122A1 (en) 1998-07-06
NO980718D0 (no) 1998-02-20
WO1997049689A1 (en) 1997-12-31
EP0853616B1 (en) 2001-09-19
HUP9902026A2 (hu) 2000-04-28
EA199800215A1 (ru) 1998-08-27
CA2228492A1 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
ES2182754T3 (es) Procedimiento para preparar comprimidos revestidos con polimero, que comprenden amoxicilina y clavulanato revestidos con un revestimiento polimero acuoso formador de pelicula.
BR0311890A (pt) Método para preparar um compósito carregado com nanotubos de carbono, compósito carregado com nanotubos de carbono, e, método para formar o mesmo
ES2113448T3 (es) Catalizador de polimerizacion de olefinas, procedimiento para su preparacion y su utilizacion.
ES2115298T3 (es) Nuevos derivados de 1-fenil-3-dimetil-amino-propano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2096696T3 (es) Composiciones poliolefinicas y procedimiento para su preparacion.
MY117138A (en) Coating of mineral moldings with radiation-curable preparations
AR011175A1 (es) Composicion que contiene compuestos de cianoacrilato, curables por radiacion, metodo para polimerizarla, y productos y articulos formados apartir de la misma
ES2177585T3 (es) Compuestos organometalicos de fluorenilo, reparacion y uso.
ES2078211T3 (es) Composicion de recubrimiento curable con ultravioleta y procedimiento para la preparacion de la misma.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
DE69729082D1 (de) Hochgesättigter nitrile-copolymer-kautschuk, verfahren zu dessen herstellung, den kautschuk enthaltende kautschukzusammensetzungen und den kautschuk und fasern enthaltende verbundmaterialien
DE69720571D1 (de) Sauerstoff absorbierende Harzzusammensetzung und Verpackungsmaterial, mehrschichtiges Verpackungsmaterial, Verpackung und Verpackungsverfahren die dieses verwendet
MX9703592A (es) Componente de catalizador soportado, catalizador soportado, su preparacion y proceso de polimerizacion por adicion.
ES2091281T3 (es) Composiciones de resina epoxidica modificadas con caucho.
BR0213277A (pt) Método de colagem de materiais à base de madeira
DE69021341D1 (de) Härtungsmittel, verfahren zu seiner herstellung und damit hergestellte härtbare zusammensetzung.
CO5040042A1 (es) Estructura absorbente que comprende un polimero absorbente, y un articulo absorbente que comprende la estructura absorbente
ES474346A1 (es) Procedimiento para preparar productos endurecibles de resinaepoxidica
FR2716622B1 (fr) Compositions cosmétiques autobronzantes à base de dihydroxyacétone, procédé de préparation et utilisation.
ES2010967T3 (es) Metodo de eliminar la pegajosidad de la pintura en cabinas de pintado con pistola.
BR0015164A (pt) Composições curável, pré-curada ou pré-impregnada, e curada, processos para a preparação de uma composição, para curar uma composição curável, para pós-curar uma resina pré-curada, ou pré-impregnada, para curar uma composição pré-curada e para o esquema de ciclo de cura para curar um composição, compósito, uso de uma ferramenta ou molde de compósito, e , uso de uma composição, resina curada, compósito ou produto conformado
DE69008122D1 (de) Phenolnovolakharz, dessen härtungsprodukt und verfahren zur herstellung.
CA2258040A1 (en) Curable thermoset resin composition
ES2063269T3 (es) Procedimiento para la preparacion de tigogenina-b-celobiosido.
BR0016846A (pt) Composição fotocurável e os produtos curados

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 853616

Country of ref document: ES